Clinical Response to Prostate Cancer Immunotherapy using GM-CSF and anti-CD152 Correlates with Diversity of Upmodulated Antibody Binding to Microarray Antigens
“Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients” Kwek S S, L Fong, et al. (Oct 2012) J Immunol 189(7): 3759-3766. “…advanced prostate cancer patients who clinically respond to treatment also develop enhanced Ab responses to a higher number of Ags than nonresponders…” Relevant Ancell Products Anti-CD152(CTLA-4) blocking mAb […]